Myo-Inositol in Polycystic Ovary Syndrome: A Systematic Review and Positioning of Its Use
March 2022
in “
International Journal of Nutrology
”
TLDR Myo-inositol improves fertility and metabolic health in PCOS with fewer side effects than metformin.
This systematic review evaluated the effects of myo-inositol (MI) on women with Polycystic Ovary Syndrome (PCOS) across 16 randomized clinical trials. MI was found to improve fertility by increasing ovulation and fertilization rates, and it enhanced metabolic parameters related to insulin resistance, showing similar efficacy to metformin but with fewer side effects. It also improved pregnancy outcomes and reduced the risk of gestational diabetes. The review highlighted MI's role in insulin signaling and follicular development, noting its safety and effectiveness in improving ovulation and pregnancy rates. However, it emphasized the need for more extensive trials to confirm these findings. The Brazilian Association of Nutrology recommended MI for PCOS patients due to its clinical benefits and favorable safety profile.